他莫昔芬精准给药:内分泌敏感乳腺癌患者的内昔芬治疗药物监测可行性
这项前瞻性开放标签干预研究纳入145例接受标准剂量他莫昔芬20 mg每日一次治疗的早期乳腺癌患者,通过治疗药物监测(TDM)在3、4.5、6个月时检测内昔芬浓度,低于16 nM者剂量上调至最大40 mg。6个月时89%的患者内昔芬水平≥16 nM,显著高于历史数据80%(95%CI 82-94,P=0.007),且剂量上调后未报告他莫昔芬相关不良事件增加。
要点
- TDM指导的他莫昔芬剂量上调可使89%患者6个月时内昔芬≥16 nM。
- 携带CYP2D6突变等位基因者并非总能达到≥16 nM的目标浓度。
- 剂量上调至最大40 mg未增加他莫昔芬相关不良事件。
核心结论
- 采用TDM可提高内昔芬水平≥16 nM的患者比例,并使内昔芬水平<16 nM的患者数量接近减半。
- TDM是一种安全的策略,但携带CYP2D6突变等位基因的患者并非总能达到目标浓度。
研究设计与样本
- 前瞻性开放标签干预研究,纳入145例开始标准剂量他莫昔芬20 mg每日一次治疗的早期乳腺癌患者。
- 在治疗开始后3、4.5、6个月时结合门诊随访采集TDM样本,内昔芬浓度<16 nM者剂量上调至最大40 mg。
- 主要终点为治疗开始后6个月时内昔芬水平≥16 nM的患者百分比,与历史数据(标准治疗下80%患者≥16 nM)比较。
主要发现
- 6个月时89%的患者内昔芬水平≥16 nM,历史数据为80%(95%CI 82-94,P=0.007)。
- 携带CYP2D6突变等位基因的患者并非总能达到≥16 nM的内昔芬目标水平。
- 剂量上调后未报告他莫昔芬相关不良事件增加。
关键数值与推荐
- 内昔芬目标水平为≥16 nM(5.97 ng/mL)。
- 他莫昔芬标准剂量为20 mg每日一次,剂量上调最大至40 mg。
- TDM采样时间点为治疗开始后3、4.5、6个月。
临床怎么用
- 对接受标准剂量他莫昔芬20 mg每日一次的早期乳腺癌患者,可在3、4.5、6个月时进行TDM。
- 内昔芬浓度<16 nM者可考虑将剂量上调至最大40 mg,并监测不良事件。
- 对携带CYP2D6突变等位基因的患者,需认识到即使上调剂量也可能无法达到目标浓度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endoxifen is the most important active metabolite of tamoxifen. Several retrospective studies have suggested a minimal or threshold endoxifen systemic concentration of 14-16 nM is required for a lower recurrence rate. The aim of this study was to investigate the feasibility of reaching a predefined endoxifen level of ≥ 16 nM (5.97 ng/mL) over time using therapeutic drug monitoring (TDM). METHODS: This prospective open-label intervention study enrolled patients who started treatment with a standard dose of tamoxifen 20 mg once daily for early breast cancer. An outpatient visit was combined with a TDM sample at 3, 4.5, and 6 months after initiation of the tamoxifen treatment. The tamoxifen dose was escalated to a maximum of 40 mg if patients had an endoxifen concentration < 16 nM. The primary endpoint of the study was the percentage of patients with an endoxifen level ≥ 16 nM at 6 months after the start of therapy compared with historical data, in other words, 80% of patients with endoxifen levels ≥ 16 nM with standard therapy. RESULTS: In total, 145 patients were included. After 6 months, 89% of the patients had endoxifen levels ≥ 16 nM, compared with a literature-based 80% of patients with endoxifen levels ≥ 16 nM at baseline (95% confidence interval 82-94; P = 0.007). In patients with an affected CYP2D6 allele, it was not always feasible to reach the predefined endoxifen level of ≥ 16 nM. No increase in tamoxifen-related adverse events was reported after dose escalation. CONCLUSION: This study demonstrated that it is feasible to increase the percentage of patients with endoxifen levels ≥ 16 nM using TDM. TDM is a safe strategy that offers the possibility of nearly halving the number of patients with endoxifen levels < 16 nM.
引用
- Braal CL, Jager A, Hoop EO, et al. Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. Clin Pharmacokinet. 2021. PMID: 34786650. doi:10.1007/s40262-021-01077-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。